Articles by Blood Cancers Today Staff Writers
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Efficacy was based on the MRD-negative CR rate at the end of induction.
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
The 11-member panel of independent experts voted eight in favor and three against.
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.
CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
The therapy is currently under investigation in multiple clinical trials.
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.